Alcon Commences Phase 2 Clinical Trial Of NovaBay's NVC-422 For Viral Conjunctivitis
Alcon, Inc. (NYSE: ACL) and its partner, NovaBay Pharmaceuticals, Inc. (NYSE-AMEX: NBY), announced that Alcon has begun treating patients in a Phase 2 clinical trial of NovaBay"s patented lead Aganocide® compound, NVC-422, for viral conjunctivitis, a type of "pink eye." Conjunctivitis is a pervasive and painful condition that affects both adults and children, leading to more than four million doctor and emergency room visits in the United States each year.
Sexual Health